Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 5/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899416 | 0.87 | KAT6A (0.57) | KAT6AHSD11B1 | |
| SCHEMBL14676121 | 0.83 | HSD11B1 (0.47) | KAT6AHSD11B1 | |
| SCHEMBL14676076 | 0.81 | SLC1A3 (0.50) | KAT6AALDH1A1 | |
| SCHEMBL3257198 | 0.81 | KAT6A (0.49) | KAT6AHSD11B1ALDH1A1TSHRGBA1 | |
| SCHEMBL14676352 | 0.81 | PTK2B (0.41) | KAT6AKMT2A | |
| SCHEMBL14676434 | 0.81 | KCNH2 (0.46) | KAT6AHSD11B1ALDH1A1 | |
| SCHEMBL14676717 | 0.81 | MEN1 (0.56) | KAT6AMEN1KMT2AALDH1A1 | |
| SCHEMBL1111509 | 0.80 | NSD2 (0.50) | KAT6AMEN1KMT2AALDH1A1GBA1 | |
| SCHEMBL14675988 | 0.80 | POLB (0.48) | — | |
| SCHEMBL14676017 | 0.80 | SLC1A3 (0.49) | HSD11B1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073830-B2 | Compound for inhibiting 11β-hydroxy steroid dehydrogenase 1, and a pharmaceutical composition comprising the same | HYUNDAI PHARM CO., LTD. (KR) | 2015-07-07 | — | — | US | disclosed |
| US-20140206875-A1 | A COMPOUND FOR INHIBITING 11B-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HYUNDAI PHARM CO., LTD. (KR) | 2014-07-24 | — | — | US | disclosed |
| WO-2013019091-A2 | A COMPOUND FOR INHIBITING 11β-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HYUNDAI PHARM CO., LTD. (KR) | 2013-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206875-A1 | A COMPOUND FOR INHIBITING 11B-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HSD11B1, HSD11B2, HSD17B1 | KAT6A 3113/4885HSD11B1 1/4885MEN1 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.